Granulomatosis with polyangiitis (GPA) is a prototypical antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis characterized by necrotizing inflammation of small- and medium-sized vessels with granulomatous features. While modern immunosuppressive therapies have markedly improved short-term survival in GPA, long-term outcomes remain constrained by cumulative organ damage, treatment-related toxicity, and an excess burden of cardiovascular morbidity and mortality.
Cardiovascular risk in GPA is multifactorial. The review emphasizes that risk appears to reflect a mix of conventional cardiovascular risk factors, metabolic effects of treatment, renal dysfunction, systemic inflammation, and disease-associated vascular injury. Consequently, cardiovascular disease in GPA likely extends beyond accelerated epicardial atherosclerosis alone and may involve the coronary microcirculation and myocardium.
Established components of ANCA-associated vasculitis (AAV) pathophysiology described in the source include neutrophil-mediated inflammation, complement amplification, endothelial dysfunction, oxidative stress, and thromboinflammatory pathways. These mechanisms are central to vascular injury in AAV and are invoked to explain how systemic immune processes could affect coronary vessels and myocardial tissue.
The review differentiates between well-established immunopathological processes observed in AAV and mechanistic links that remain theoretical for GPA-specific coronary microvascular involvement. It stresses that some mechanistic relationships are extrapolated from experimental models or the broader cardiovascular literature rather than demonstrated conclusively in human GPA cohorts.
The review highlights that coronary microvascular dysfunction (CMD) has not been definitively characterized in GPA. Although CMD is biologically plausible in the context of ANCA-mediated vascular injury and systemic inflammation, the prevalence, precise mechanisms, and prognostic significance of CMD specifically in GPA remain insufficiently demonstrated by dedicated human studies.
Available observations linking AAV-related vascular inflammation to impaired myocardial perfusion and CMD are described as hypothesis-generating. The authors caution that current evidence does not establish causality or frequency of CMD in GPA and that dedicated prospective, GPA-specific investigations are needed to fill these knowledge gaps.
Cardiac magnetic resonance (CMR) studies in GPA and the broader AAV population have identified myocardial abnormalities. Reported findings include late gadolinium enhancement (LGE), inflammatory changes, and fibrotic remodeling. Notably, such imaging abnormalities have been observed sometimes in patients without overt cardiac symptoms.
However, the review notes that CMR observations alone do not define whether myocardial abnormalities reflect prior epicardial ischemia, microvascular dysfunction, direct inflammatory myocardial involvement, or a combination of these processes. The relationship between imaging findings and clinical outcomes in GPA remains to be clarified by prospective research.
The review sets out a biologically plausible sequence whereby ANCA-mediated and complement-amplified inflammation could impair endothelial function and promote oxidative stress and thromboinflammatory activity within coronary microvessels. Repetitive low-grade ischemia from microvascular dysfunction could then contribute to myocardial fibrosis and arrhythmogenic remodeling.
Authors emphasize that these proposed links are partly extrapolated and should currently be viewed as hypotheses. Experimental AAV models and analogies from broader cardiovascular research support plausibility, but direct human evidence specific to GPA—quantifying ischemia burden, linking it to fibrosis, and demonstrating downstream clinical consequences—was not reported in the source.
The review advocates a GPA-specific, coronary microcirculation–centered perspective within an emerging immunocardiology framework. It discusses potential roles for advanced cardiovascular imaging (including CMR), individualized cardiovascular risk assessment, and targeted cardiovascular evaluation in selected patients with GPA.
At present, the review distinguishes established clinical observations (such as increased cardiovascular morbidity and the presence of CMR abnormalities in some patients) from proposed mechanistic relationships (such as CMD-driven ischemia leading to fibrosis). Specific screening algorithms, surveillance intervals, or proven cardioprotective strategies in GPA were not provided in the source and therefore remain to be defined by future studies.
The authors conclude that prospective, GPA-specific studies are required to determine the clinical significance of coronary microvascular dysfunction and to establish whether targeted cardiovascular monitoring or cardioprotective interventions alter outcomes. The review calls for research that integrates immunopathological assessment, advanced imaging, and careful clinical phenotyping to move from plausibility to evidence.
In summary, the source frames coronary microvascular dysfunction and myocardial involvement in GPA as biologically plausible and supported by imaging signals in AAV, but currently insufficiently proven in human GPA populations. The review seeks to separate confirmed observations from hypotheses and to highlight priorities for future prospective investigation within an immunocardiology paradigm.